Genmab Statistics
Total Valuation
Genmab has a market cap or net worth of $33.05 billion. The enterprise value is $36.29 billion.
| Market Cap | 33.05B |
| Enterprise Value | 36.29B |
Important Dates
The last earnings date was Thursday, November 5, 2026.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Genmab has 63.30 million shares outstanding. The number of shares has decreased by -1.08% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 63.30M |
| Shares Change (YoY) | -1.08% |
| Shares Change (QoQ) | +0.58% |
| Owned by Insiders (%) | 1.10% |
| Owned by Institutions (%) | 59.48% |
| Float | 58.91M |
Valuation Ratios
The trailing PE ratio is 45.45 and the forward PE ratio is 30.53.
| PE Ratio | 45.45 |
| Forward PE | 30.53 |
| PS Ratio | 7.69 |
| Forward PS | 6.06 |
| PB Ratio | 5.22 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 38.84 |
| P/OCF Ratio | 37.77 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 26.76, with an EV/FCF ratio of 42.64.
| EV / Earnings | 49.78 |
| EV / Sales | 8.45 |
| EV / EBITDA | 26.76 |
| EV / EBIT | 27.58 |
| EV / FCF | 42.64 |
Financial Position
The company has a current ratio of 2.45, with a Debt / Equity ratio of 0.82.
| Current Ratio | 2.45 |
| Quick Ratio | 2.43 |
| Debt / Equity | 0.82 |
| Debt / EBITDA | 3.78 |
| Debt / FCF | 6.11 |
| Interest Coverage | 3.49 |
Financial Efficiency
Return on equity (ROE) is 12.07% and return on invested capital (ROIC) is 12.73%.
| Return on Equity (ROE) | 12.07% |
| Return on Assets (ROA) | 8.24% |
| Return on Invested Capital (ROIC) | 12.73% |
| Return on Capital Employed (ROCE) | 11.31% |
| Weighted Average Cost of Capital (WACC) | 7.19% |
| Revenue Per Employee | $1.32M |
| Profits Per Employee | $224,723 |
| Employee Count | 3,244 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 14.32 |
Taxes
In the past 12 months, Genmab has paid $49.00 million in taxes.
| Income Tax | 49.00M |
| Effective Tax Rate | 6.30% |
Stock Price Statistics
The stock price has increased by +70.70% in the last 52 weeks. The beta is 0.55, so Genmab's price volatility has been lower than the market average.
| Beta (5Y) | 0.55 |
| 52-Week Price Change | +70.70% |
| 50-Day Moving Average | 40.81 |
| 200-Day Moving Average | 31.45 |
| Relative Strength Index (RSI) | 60.20 |
| Average Volume (20 Days) | 6,514,015 |
Short Selling Information
The latest short interest is 6.60 million, so 1.09% of the outstanding shares have been sold short.
| Short Interest | 6.60M |
| Short Previous Month | 6.06M |
| Short % of Shares Out | 1.09% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.67 |
Income Statement
In the last 12 months, Genmab had revenue of $4.30 billion and earned $729.00 million in profits. Earnings per share was $1.14.
| Revenue | 4.30B |
| Gross Profit | 3.98B |
| Operating Income | 1.32B |
| Pretax Income | 778.00M |
| Net Income | 729.00M |
| EBITDA | 1.36B |
| EBIT | 1.32B |
| Earnings Per Share (EPS) | $1.14 |
Balance Sheet
The company has $1.87 billion in cash and $5.20 billion in debt, with a net cash position of -$3.33 billion or -$5.26 per share.
| Cash & Cash Equivalents | 1.87B |
| Total Debt | 5.20B |
| Net Cash | -3.33B |
| Net Cash Per Share | -$5.26 |
| Equity (Book Value) | 6.33B |
| Book Value Per Share | 10.01 |
| Working Capital | 1.89B |
Cash Flow
In the last 12 months, operating cash flow was $875.00 million and capital expenditures -$24.00 million, giving a free cash flow of $851.00 million.
| Operating Cash Flow | 875.00M |
| Capital Expenditures | -24.00M |
| Depreciation & Amortization | 40.00M |
| Net Borrowing | 5.20B |
| Free Cash Flow | 851.00M |
| FCF Per Share | $1.34 |
Margins
Gross margin is 92.67%, with operating and profit margins of 30.63% and 16.97%.
| Gross Margin | 92.67% |
| Operating Margin | 30.63% |
| Pretax Margin | 18.11% |
| Profit Margin | 16.97% |
| EBITDA Margin | 31.56% |
| EBIT Margin | 30.63% |
| FCF Margin | 19.81% |
Dividends & Yields
Genmab does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 1.08% |
| Shareholder Yield | 1.08% |
| Earnings Yield | 2.20% |
| FCF Yield | 2.57% |
Analyst Forecast
The average price target for Genmab is $65.10, which is 25.82% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $65.10 |
| Price Target Difference | 25.82% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | 26.12% |
| EPS Growth Forecast (3Y) | 22.17% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Stock Splits
The last stock split was on May 1, 2018. It was a forward split with a ratio of 5:1.
| Last Split Date | May 1, 2018 |
| Split Type | Forward |
| Split Ratio | 5:1 |
Scores
Genmab has an Altman Z-Score of 3.02 and a Piotroski F-Score of 4.
| Altman Z-Score | 3.02 |
| Piotroski F-Score | 4 |